{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-059386","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.932954+00:00","generated_at":"2026-06-08T21:03:50.497837+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vaxcyte Q3 net loss $92.7M; FDA clears VAX-31 IND; VAX-24 Phase 3 agreed","bullets":["Net loss $92.7M vs $57.9M YoY; cash $1.43B (up from $957.9M Dec 2022).","Completed End-of-Phase 2 FDA meeting for VAX-24 adult Phase 3; topline data expected 2025.","FDA cleared VAX-31 adult IND; Phase 1/2 starts Q4 2023, topline data H2 2024.","Expanded Lonza collaboration for commercial manufacturing of VAX-24 and VAX-31.","VAX-24 infant Phase 2 advanced to Stage 2 with comparator Prevnar 20."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-059386","json":"https://secwatch.observer/filing/0000950170-23-059386.json","markdown":"https://secwatch.observer/filing/0000950170-23-059386.md","text":"https://secwatch.observer/filing/0000950170-23-059386.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000095017023059386/0000950170-23-059386-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000095017023059386/pcvx-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:03:50.497837+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}